RT Journal Article
SR Electronic
T1 Social interventions can lower COVID-19 deaths in middle-income countries
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.16.20063727
DO 10.1101/2020.04.16.20063727
A1 Paternina-Caicedo, Angel
A1 Choisy, Marc
A1 Garcia-Calavaro, Christian
A1 España, Guido
A1 Rojas-Suarez, José
A1 Dueñas, Carmelo
A1 Smith, Adrian
A1 De la Hoz-Restrepo, Fernando
YR 2020
UL http://medrxiv.org/content/early/2020/04/23/2020.04.16.20063727.abstract
AB A novel pandemic coronavirus disease (COVID-19) was first detected in late 2019 in Wuhan (China)1,2. COVID-19 has caused 77 national governments worldwide to impose a lockdown in part or all their countries, as of April 4, 20203. The United States and the United Kingdom estimated the effectiveness of non-pharmaceutical interventions to reduce COVID-19 deaths, but there is less evidence to support choice of control measures in middle-income countries4. We used Colombia, an upper-middle income country, as a case-study to assess the effect of social interventions to suppress or mitigate the COVID-19 pandemic. Here we show that a combination of social distancing interventions, triggered by critical care admissions, can suppress and mitigate the peak of COVID-19, resulting in less critical care use, hospitalizations, and deaths. We found, through a mathematical simulation model, that a one-time social intervention may delay the number of critical care admissions and deaths related to the COVID-19 pandemic. However, a series of social interventions (social and work distance and school closures) over a period of a year can reduce the expected burden of COVID-19, however, these interventions imply long periods of lockdown. Colombia would prevent up to 97% of COVID-19 deaths using these triggered series of interventions during the first year. Our analyses could be used by decision-makers from other middle-income countries with similar demographics and contact patterns to Colombia to reduce COVID-19 critical care admissions and deaths in their jurisdictions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe did not have funding for this manuscript.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used for the present study is open data. Readers wishing to replicate the study can access the data under a reasonable request to the corresponding author.